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This special issue of the International Journal of Alzheimer’s
disease contains a series of cuttingedge articles that deal
with the broad issue of inﬂammatory and immunological
disease mechanisms of Alzheimer disease (AD). Of necessity,
these articles focus on selected topics but the mixture of
contributions on signaling pathways, mediators, and articles
addressing cell lines provides an overview and an insight into
current areas of debate in inﬂammation and neurodegen-
eration. In particular, they highlight current interest in the
interface between innate and adaptive immunity and present
intriguing prospects for future therapeutic developments in
neuroinﬂammation areas.
Immunohistochemical and molecular biological evi-
dence accumulated over the past two decades has shown
that the brain is capable of sustaining an innate immune
response and that the result may be damaging to host cells.
Neuroinﬂammation is a characteristic feature of both acute
and chronic CNS disorders and is a process that results
primarily from the presence of chronically activated glial
cells (astrocytes and microglia) in the brain, and is a com-
mon feature of several neurodegenerative conditions. The
evidence for a chronic inﬂammatory reaction in the brain
is particularly strong in AD where it has been extensively
studied. Mounting evidence indicates that microglial activa-
tion contributes to neuronal damage in neurodegenerative
diseases, but beneﬁcial aspects have also been identiﬁed.
The concept that neuroinﬂammation is detrimental implies
that glial cell activation precedes and causes neuronal
degeneration, a sequence of events that appears to be at odds
with experimental models of neurodegeneration in which
glial cell activation occurs secondary to neuronal damage.
There is abundant evidence that numerous substances
involved in the promotion of inﬂammatory processes are
present in the CNS of patients with such neurodegenerative
diseases. Inﬂammation in the brain is silent because the
brain does not possess pain ﬁbers. It depends upon synthesis
of inﬂammatory components by local neurons and glia,
and especially resident phagocytes which, in the brain, are
the microglia. Microglia, inﬂammatory cytokines, and the
complement system appear to play signiﬁcant roles.
Dementia is a decline of cognitive functions (reasoning,
memory, and other mental abilities). This decline eventually
impairs the ability to carry out mundane activities such as
driving;householdchores,andpersonalcaresuchasbathing,
dressing, and feeding (often denoted as activities of daily
living), or ADL.
Proinﬂammatory mediators released by activated glial
cells during brain inﬂammation have been proposed to
contribute to neuropathology underlying cognitive deﬁcits.
Three major pathologies characterize the disease: senile
plaques, neuroﬁbrillary tangles, and inﬂammation. What
distinguishes AD from other neurodegenerative diseases is
the conspicuous presence of extracellular amyloid deposits
in senile plaques, dystrophic neurite growth, and excessive
tau phosphorylation. Senile plaques in AD brain are present
in diﬀerent stages of maturity, ranging from diﬀuse to
neuritic to dense core, but they all contain amyloid beta
protein (Aβ). Aβ is a peptide that forms insoluble and2 International Journal of Alzheimer’s Disease
pathological extracellular aggregates that attract microglial
cells, as suggested by microglia clustering at Aβ deposition
sites.
Duleu et al., using an improved ELISA procedure,
observed in AD patient sera, circulating IgA isotype antibod-
ies directed against tryptophan metabolites. The paper con-
ﬁrms that neurotoxic tryptophan metabolites are implicated
in neurodegenerative diseases. The activation of the IDO
pathway leads to an over expression of tryptophan metabo-
lites, which are implicated in neuroinﬂammation in AD.
The identiﬁcation of circulating antibodies directed against
IDO/THO pathway metabolites elucidates the etiology of
AD.
In the paper entitled “Microglial immunoreceptor
tyrosine-based activation and inhibition motif signaling
in neuroinﬂammation,” Linnartz et al. reviewed the
involvement of ITAM- and ITIMsignaling receptors
in the central nervous system (CNS) innate immune
responses and neuroinﬂammation as modulator of
microglial phagocytosis and cytokine expression. In the
mammalian CNS, essential molecules in this process are
Fc receptors and DAP12-associated receptors which trigger
the microglial immunoreceptor tyrosine-based activation
motif (ITAM)-Syk-signaling cascade. The authors indicated
how ITAM- and ITIM-signaling receptors modulate
microglial phagocytosis and cytokine expression during
neuroinﬂammatory processes. They also described how their
dysfunction could lead to impaired phagocytic clearance and
neurodegeneration triggered by chronic inﬂammation.
Hjorth et al. using human CHME3 microglia showed
intracellular Aβ1–42 colocalized with lysosome-associated
membrane protein-2. This indicated that phagocytosis was
increasedbyinterferon-γ,andtoalesserdegree,byProtollin,
a proteasome-based adjuvant. Phagocytosis of Aβ1–42 is asso-
ciated with the expression of inﬂammatory markers. Aβ1–42
and interferon-γ decreased BDNF secretion suggesting a
new neuropathological role for Aβ1–42 and inﬂammation
accompanying AD.
In another review, Dyall described neuroprotective
eﬀects of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) in AD. Inﬂammation and oxidative stress appear
to be key features contributing to AD, and omega-3 polyun-
saturated fats, EPA, and DHA have wellcharacterised eﬀects
on inﬂammation and may have neuroprotective eﬀects in a
number of neurodegenerative conditions. The role of EPA
and DHA in modulating oxidative stress and inﬂammation
and their potential as therapeutic agents were emphasized.
In the paper entitled “Interleukin-10 promoter poly-
morphism in mild cognitive impairment and in its clinical
evolution,” Arosio et al. strengthen the theory that the overall
risk of developing AD may be governed by a multifactorial
“susceptibility proﬁle” and that polymorphisms of cytokine
genes can aﬀect neurodegeneration and its clinical progres-
sion. In their study, the authors have analysed genotype and
allele frequencies of A allele of −1082 polymorphism (G/A)
of interleukin-10 (IL-10) in 138 subjects with mild cognitive
impairment (MCI) diagnosed respectively as amnestic (a-
MCI) and multiple impaired cognitive domains (mcd-MCI).
T h eh o m o z y g o s i sf o rt h eAa l l e l eo ft h i sp o l y m o r p h i s m
of IL-10 promotes an higher risk of AD and reduced IL-
10 generation in peripheral cells after amyloid stimulation.
Thus, the authors proposed thatIL-10 may partly explain the
conversion of a-MCI to AD or, at least, be a genetic marker
of susceptibility.
T h eﬁ n a lp a p e ro ft h i ss p e c i a li s s u eb yK r a u s ee ta l .
reviews the detrimental and beneﬁcial role of neuroinﬂam-
mation in AD. The authors focus on controversies in the
ﬁeld of microglia activation, attempting to shed light on
whether neuroinﬂammation is associated with brain tissue
damage and functional impairment or whether damage-
limitingactivityoccurs.Thepossiblelimitations,optionsand
advantages of anti-inﬂammatory treatment are discussed
and possible implications resulting from neuroinﬂammation
for AD therapy.
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